Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials

Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

(2013) Roberto Latini et al.   AMERICAN HEART JOURNAL

Antihypertensive treatment and risk of atrial fibrillation: a nationwide study

(2013) Sarah C.W. Marott et al.   EUROPEAN HEART JOURNAL

Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy

(2013) Milton Packer et al.   JACC-Heart Failure

The Global Burden of Atrial Fibrillation and Stroke

(2012) Gregory Y.H. Lip et al.   CHEST

Antiarrhythmic Drug Therapy for Atrial Fibrillation

(2012) Peter Zimetbaum   CIRCULATION

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials

(2012) Kazem Rahimi et al.   PLOS MEDICINE

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention

(2011) I. Savelieva et al.   EUROPACE

Irbesartan in Patients with Atrial Fibrillation

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPACE

Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition

(2010) Markus P. Schneider et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs

(2009) Janice Pogue et al.   Clinical Trials

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study

(2009) X. Du et al.   EUROPEAN HEART JOURNAL

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

(2009) Roland E Schmieder et al.   JOURNAL OF HYPERTENSION

Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

(2009) L. Julian Haywood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial

(2009) Paolo Verdecchia et al.   LANCET

Valsartan for Prevention of Recurrent Atrial Fibrillation

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Atrial Fibrillation and Isolated Systolic Hypertension

(2008) Tudor D. Vagaonescu et al.   HYPERTENSION

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

(2008) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE